Pharma Mar S.A. - Asset Resilience Ratio
Pharma Mar S.A. (PHM) has an Asset Resilience Ratio of 37.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Pharma Mar S.A.'s Asset Resilience Ratio has changed over time. Check Pharma Mar S.A. (PHM) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pharma Mar S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pharma Mar S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €149.41 Million | 37.82% |
| Total Liquid Assets | €149.41 Million | 37.82% |
Asset Resilience Insights
- Very High Liquidity: Pharma Mar S.A. maintains exceptional liquid asset reserves at 37.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pharma Mar S.A. Industry Peers by Asset Resilience Ratio
Compare Pharma Mar S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896 |
Biotechnology | 12.69% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
Annual Asset Resilience Ratio for Pharma Mar S.A. (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Pharma Mar S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.82% | €149.41 Million ≈ $174.67 Million |
€395.08 Million ≈ $461.89 Million |
+11.71pp |
| 2024-12-31 | 26.11% | €91.29 Million ≈ $106.73 Million |
€349.64 Million ≈ $408.77 Million |
-4.00pp |
| 2023-12-31 | 30.11% | €102.54 Million ≈ $119.88 Million |
€340.52 Million ≈ $398.10 Million |
+14.67pp |
| 2022-12-31 | 15.44% | €60.73 Million ≈ $71.00 Million |
€393.26 Million ≈ $459.76 Million |
-8.59pp |
| 2021-12-31 | 24.03% | €88.53 Million ≈ $103.50 Million |
€368.39 Million ≈ $430.68 Million |
-6.04pp |
| 2020-12-31 | 30.07% | €99.31 Million ≈ $116.10 Million |
€330.26 Million ≈ $386.11 Million |
+27.46pp |
| 2019-12-31 | 2.61% | €3.26 Million ≈ $3.81 Million |
€124.70 Million ≈ $145.79 Million |
-0.01pp |
| 2018-12-31 | 2.62% | €4.13 Million ≈ $4.83 Million |
€157.68 Million ≈ $184.34 Million |
-1.47pp |
| 2017-12-31 | 4.09% | €7.67 Million ≈ $8.97 Million |
€187.72 Million ≈ $219.46 Million |
-4.09pp |
| 2016-12-31 | 8.17% | €18.08 Million ≈ $21.13 Million |
€221.14 Million ≈ $258.53 Million |
-9.75pp |
| 2015-12-31 | 17.93% | €38.00 Million ≈ $44.42 Million |
€211.94 Million ≈ $247.78 Million |
+8.51pp |
| 2014-12-31 | 9.41% | €18.96 Million ≈ $22.17 Million |
€201.39 Million ≈ $235.44 Million |
+6.05pp |
| 2013-12-31 | 3.37% | €6.38 Million ≈ $7.46 Million |
€189.37 Million ≈ $221.39 Million |
-4.69pp |
| 2012-12-31 | 8.05% | €16.09 Million ≈ $18.81 Million |
€199.83 Million ≈ $233.62 Million |
-0.64pp |
| 2011-12-31 | 8.70% | €18.94 Million ≈ $22.15 Million |
€217.82 Million ≈ $254.65 Million |
-2.56pp |
| 2010-12-31 | 11.26% | €25.98 Million ≈ $30.38 Million |
€230.82 Million ≈ $269.86 Million |
-53.90pp |
| 2005-12-31 | 65.16% | €256.54 Million ≈ $299.92 Million |
€393.72 Million ≈ $460.30 Million |
+6.03pp |
| 2004-12-31 | 59.13% | €199.46 Million ≈ $233.19 Million |
€337.34 Million ≈ $394.38 Million |
-- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more